Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
NCT04808999
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Squamous Cell Carcinoma
Interventions
DRUG:
Pembrolizumab Injection
Sponsor
Diwakar Davar
Collaborators
[object Object]